NDA 217347 · Botanix Sb
Sofdra
Sofpironium Bromide · Topical
NovelCDER novel approval, Jun 18, 2024: To treat primary axillary hyperhidrosis
Last checked: Nov 19, 2026Latest source record: Jun 18, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Jun 18, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
6
3 Phase 3, 0 recruiting
FAERS reports
281
34 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 22, 2025.
SOFDRA is indicated for the treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older. SOFDRA is an anticholinergic indicated for the treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older ( 1 ).
Mechanism: Sofpironium bromide is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including sweat glands. Sofpironium bromide indirectly reduces the rate of sweating by preventing the stimulation of these receptors.
Therapeutic areas: Dermatology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- SOFDRA · SOFPIRONIUM BROMIDE EQ 12.45% BASE (EQ 72MG BASE/ACTUATION) · GEL, METERED, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sofpironium" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)Pivotal-lookingCompleted
Botanix PharmaceuticalsIndustry
NCT03948646 · 351 participants · Start Dec 4, 2020 · Primary completion Aug 13, 2021
Drug: Sofpironium Bromide, 15%; Vehicle · For: Axillary Hyperhidrosis
Sites: Birmingham, Alabama; Glendale, Arizona; North Little Rock, Arkansas · 42 sites in all
- Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)Pivotal-lookingCompleted
Botanix PharmaceuticalsIndustry
NCT03836287 · 350 participants · Start Oct 9, 2020 · Primary completion Jun 25, 2021
Drug: Sofpironium Bromide Gel, 15%; Vehicle · For: Axillary Hyperhidrosis
Sites: Birmingham, Alabama; Scottsdale, Arizona; Rogers, Arkansas · 39 sites in all
- A Safety Study of BBI-4000 Gel in Patients With Axillary HyperhidrosisPivotal-lookingCompleted
Botanix PharmaceuticalsIndustry
NCT03627468 · 300 participants · Start Sep 5, 2018 · Primary completion Jan 27, 2020
Drug: Sofpironium Bromide Gel, 5%; Sofpironium Bromide Gel, 15% · For: Primary Axillary Hyperhidrosis
Sites: Mobile, Alabama; Rogers, Arkansas; Aventura, Florida · 12 sites in all
- A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary HyperhidrosisPivotal-lookingCompleted
Botanix PharmaceuticalsIndustry
NCT03024255 · 227 participants · Start Dec 22, 2016 · Primary completion Sep 19, 2017
Drug: BBI-4000 gel, 5%; BBI-4000 gel, 10% and 2 more · For: Hyperhidrosis
Botanix PharmaceuticalsIndustry
NCT02682238 · 50 participants · Start Mar 8, 2016 · Primary completion Jul 14, 2016
Drug: BBI-4000, 15% · For: Hyperhidrosis
Sites: San Diego, California; Miami, Florida; Carmel, Indiana · 5 sites in all
Botanix PharmaceuticalsIndustry
NCT03785587 · 21 participants · Start Dec 21, 2018 · Primary completion Sep 6, 2019
Drug: Sofpironium Bromide Gel, 15% · For: Primary Axillary Hyperhidrosis
Sites: Rogers, Arkansas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- vision blurred102
- dry mouth63
- application site pain39
- mydriasis31
- application site irritation26
- drug ineffective24
- rash24
- application site rash23
- urinary retention23
- off label use14
- dysuria12
- application site erythema10
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 2 |
| 2025 | 130 |
| 2026 | 149 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sofpironium topical gel, 12.45%, for the treatment of axillary hyperhidrosis: Pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studies.
Pariser D, Glaser DA, Del Rosso J, et al. · J Am Acad Dermatol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of sofpironium in treatment of primary hyperhidrosis: a systematic review.
Odat RM, Yousef Aldalati A, Hammadeh BM, et al. · J Dermatolog Treat 2025 · Systematic Review
- A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.
Yokozeki H, Fujimoto T, Abe Y, et al. · J Dermatol 2021 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial.
Kirsch B, Smith S, Cohen J, et al. · J Am Acad Dermatol 2020 · Clinical Trial, Phase II, Multicenter Study
- Efficacy and Safety of Topical Anticholinergics in the Treatment of Primary Axillary Hyperhidrosis: A Systematic Review and Meta-analysis.
Kim J, Han N, Koo H, et al. · Clin Drug Investig 2026 · Systematic Review, Meta-Analysis
- A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.
Fujimoto T, Abe Y, Igarashi M, et al. · J Dermatol 2021 · Clinical Trial, Phase II
Sponsor: Botanix Sb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.